◎
See Isoforms
Reveal protein variants that remain invisible to conventional antibodies.
Isoform-specific nanobodies
Unlocking the Hidden Biology of Protein Isoforms
IsoBodies develops isoform-specific nanobodies that distinguish disease-linked protein variants invisible to conventional antibodies.
By combining expertise in alternative splicing, disease biology, and nanobody engineering, we are building the next generation of tools for research, diagnostics, and therapeutics.
Y
Precision Nanobodies
Approximately 10× smaller than conventional IgG antibodies, with exceptional specificity.
≋
Dual Selection
Alpaca immune training plus phage-display screening to identify selective candidates.
Founder introduction
Why IsoBodies Exists
Dr. Dimitri Traenkner explains how alternative splicing creates hidden biological diversity and why isoform-specific nanobodies represent a new frontier in research, diagnostics, and therapeutics.
The Problem
Alternative splicing creates multiple protein isoforms from a single gene. Many diseases are driven by specific isoforms, yet existing antibodies generally cannot distinguish between them.
Our Solution
IsoBodies develops highly selective nanobodies that recognize specific protein isoforms, allowing researchers to study disease-relevant protein variants with new precision.
Our Impact
- Advance basic research
- Enable biomarker discovery
- Support diagnostic development
- Drive future therapeutic innovation
Our Market
The global antibody and protein detection reagent market is large and growing, while demand for isoform-specific tools remains unmet.
$4–6B
>5% CAGR
Why nanobodies?
Smaller. More Precise. More Versatile.
Nanobodies are naturally occurring single-domain antibodies approximately 15 kDa in size — about ten times smaller than conventional IgG antibodies.
~15 kDaCompact structure
AccessRecognize difficult epitopes
SpecificityDesigned for precision
StableReliable production
EngineerableDiagnostics and therapeutics
Our discovery approach
From Disease-Relevant Isoforms to Validated ISOBODs
1Identify Targets
Disease-driven isoform selection using literature, data, and community demand.
2Produce Antigens
Recombinant isoform antigens are produced for selection.
3Immune Training
Alpaca immune systems are trained with selected targets.
4Select Candidates
Phage display identifies the most selective nanobodies.
5Validate
Lead candidates are produced and rigorously validated.
6Serve Scientists
High-quality ISOBODs delivered to researchers worldwide.
Our team
Dr. Dimitri Traenkner
Co-Founder
Research Assistant Professor, Department of Neurobiology, University of Utah.
Dr. Peter Durcan
Co-Founder
Chief Scientific Officer and Co-Founder of AfroBodies.
Strategic partnership
AfroBodies
IsoBodies works in partnership with AfroBodies to support efficient nanobody discovery and development.
Together, we combine isoform biology with an established nanobody generation platform.
Educational explainer
Understanding Protein Isoforms
Learn how alternative splicing generates multiple protein variants from a single gene and why this hidden layer of biology matters.
Let’s connect
We welcome investor, partnership, and scientific collaboration inquiries.
info@isobodies.comAlternative splicing creates thousands of protein isoforms that shape human biology and disease. IsoBodies is building the tools needed to see them, study them, and ultimately target them.